Josh Jennings
Stock Analyst at Morgan Stanley
(2.64)
# 2,102
Out of 4,931 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $29.08 | +82.26% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $303.55 | -1.17% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $1.39 | +1,338.85% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $18.87 | +233.86% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.89 | +683.70% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $77.93 | -48.67% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $29.08
Upside: +82.26%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $303.55
Upside: -1.17%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $1.39
Upside: +1,338.85%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $18.87
Upside: +233.86%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.89
Upside: +683.70%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $77.93
Upside: -48.67%